Actinium Pharmaceuticals, Inc. — Investor Relations & Filings
Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DECEMBER 31, 2009 10K | 2010-03-16 | English | |
| Regulatory Filings 2010 | 2010-01-11 | English | |
| Regulatory Filings 2009 | 2009-12-29 | English | |
| SEPTEMBER 30, 2009 10-Q/A | 2009-12-29 | English | |
| JUNE 30, 2009 10-Q/A | 2009-12-29 | English | |
| MARCH 31, 2009 10-Q/A | 2009-12-29 | English |
Browse filings by year
20 years- 2026 4 filings
- 2025 18 filings
- 2024 21 filings
- 2023 18 filings
- 2022 21 filings
- 2021 17 filings
- 2020 44 filings
- 2019 29 filings
- 2018 49 filings
- 2017 50 filings
- 2016 38 filings
- 2015 29 filings
- 2014 42 filings
- 2013 68 filings
- 2012 10 filings
- 2011 4 filings
- 2010 5 filings
- 2009 12 filings
- 2008 5 filings
- 2007 9 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2010
2 filings
| |||||
| 12105255 | DECEMBER 31, 2009 10K | 2010-03-16 | English | ||
| 12105256 | Regulatory Filings 2010 | 2010-01-11 | English | ||
|
2009
12 filings
| |||||
| 12105262 | Regulatory Filings 2009 | 2009-12-29 | English | ||
| 12105258 | SEPTEMBER 30, 2009 10-Q/A | 2009-12-29 | English | ||
| 12105259 | JUNE 30, 2009 10-Q/A | 2009-12-29 | English | ||
| 12105260 | MARCH 31, 2009 10-Q/A | 2009-12-29 | English | ||
| 12105261 | DECEMBER 31, 2008 10-Q/A | 2009-12-29 | English | ||
| 12105263 | Regulatory Filings 2009 | 2009-12-28 | English | ||
| 12105264 | Regulatory Filings 2009 | 2009-12-15 | English | ||
| 12105265 | Regulatory Filings 2009 | 2009-11-13 | English | ||
| 12105266 | FORM 10Q QUARTERLY REPORT | 2009-11-12 | English | ||
| 12105267 | FORM 10Q QUARTERLY REPORT | 2009-08-11 | English | ||
| 12105268 | MARCH 31, 2009 10-Q | 2009-05-13 | English | ||
| 12105269 | FORM 10K ANNUAL REPORT | 2009-02-20 | English | ||
|
2008
1 filing
| |||||
| 12105270 | CACTUS VENTURES, INC. 10Q 9.30.08 | 2008-11-10 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Actinium Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34570/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34570 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34570 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34570 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34570}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Actinium Pharmaceuticals, Inc. (id: 34570)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.